Yesterday's Market and CytomX Therapeutics May 12, 2025 was an excellent day for many stressed countries. The good day began following the U.S. and China’s announcement of an agreement on Tariffs Many countries have been stressed since being attacked by COVID-19 and then the war in Europe and the Middle East as well as unparallelled inflations. Yesterday, the Stock market rallied and with it …
CytomX Therapeutics CytomX Therapeutics, Inc. (CTMX) announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose escalation update on Wednesday, May 8, 2024, after the close of U.S. markets. Following the announcement the company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the . . . This content …
CytomX Therapeutics We posted several articles that brought good news from CytomX Therapeutics (CTMX), yet the stock continues to go down instead of up. A few days ago, CytomX announced the achievement of a clinical candidate milestone under its agreement with Astellas. The clinical . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
CytomX and Moderna in the NEWS On January 05, 2023, CytomX Therapeutics (CTMX) and Moderna Inc (MRNA) announced a collaboration and licensing agreement to create . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
CytomX Therapeutics Update CytomX Therapeutics (CTMX) announced plans to focus on its emerging preclinical and early clinical pipeline and realign its capital resources to drive these efforts. Sean McCarthy, D.Phil. Chief Executive Officer and Chairman, CytomX Therapeutics, said, “With the Probody® therapeutic platform, CytomX has pioneered a new and strategic field of biologics drug discovery and development. Our leadership position will continue as we incorporate …
The Week in Review #51 Questions & Answers About CytomX Q: Is there any reason for the CytomX stock selloff that occurred in early May? In order to answer this question we need to explain CytomX’s (CTMX) Probody therapeutics. These novel treatments are designed to remain inactive until they are activated only . . . This content is for paid subscribers. Please click here to subscribe …
CytomX Therapeutics CytomX (CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® technology platform for cancer treatments. CytomX’s Probody therapeutics remain inactive until they are activated by proteases in the tumor microenvironment. Why This is Important By . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
The Week in Review #8 Potential biotech winners inspired through COLLABORATION - When successful top-tier drug developing firms such as Amgen (AMGN) or Merck (MRK) sign strategic collaborating agreements with small development-stage biotech firms,...   . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
The Week in Review #7 A lot more happened in the past week regarding improving the treatment of cancer and of other devastating diseases. This issue contains discoveries that aim at improving breakthrough immuno-oncology treatment outcomes. Here are some of the breakthrough technologies and treatments that might improve, by-far, the management of cancer . . . This content is for paid subscribers. Please click here to …
Prohost Letter #408 AT A GLANCE - Continued from the Previous Prohost Letter #408 In the Past issue #407, we picked the following firms: NEUROCRINE BIOSCIENCES (NBIX) Treating Tardive Dyskinesia CYTOMX Improving On Cancer Immunotherapy CELYAD SA (CYAD) Bringing Solutions To Immunotherapy Problems Please Read the articles written about these firms in the Issue #407 In This Issue We Add NEW LINK GENETICS...
Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE BIOSCIENCES On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbenazine) capsules for adults with tardive dyskinesia (TD), we posted an article titled “Time for Transformation and Achievements”. In the article, we stated that Neurocrine Sciences Ingrezza will highlight Neurocrine Biosciences and its …
Everybody knows Bristol-Myers Squibb (BMY), but just a few may know anything about CytomX Therapeutics (CTMX), or about its Probody Program. CytomX is a small, develop-ment-stage firm that created platform known as the Probody Program, which leads to the creation of first in class Probody therapeutics. These therapeutics are meant to overcome safety and efficacy problems encountered by the antibodies that are currently used in …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.